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Opinion TRENDS in Pharmacological Sciences Vol.27 No.11Carbonic anhydrase isoform IX (CA IX) is highly
overexpressed in many types of cancer. Its expression,
which is regulated by the HIF-1 transcription factor, is
strongly induced by hypoxia and correlates with a poor
response to classical chemo- and radiotherapies. CA IX
contributes to acidification of the tumor environment by
efficiently catalyzing the hydration of carbon dioxide to
bicarbonate and protons, thereby leading to acquisition
of metastasic phenotypes and chemoresistance to
weakly basic anticancer drugs. Inhibition of this enzy-
matic activity by specific inhibitors, such as the sulfona-
mide indisulam, reverts these processes, establishing a
clear-cut role for CA IX in tumorigenesis. Thus, selective
CA IX inhibitors could prove useful for elucidating the
role of CA IX in hypoxic cancers, for controlling the
pH imbalance in tumor cells and for developing
diagnostic or therapeutic applications for tumor
management. Indeed, fluorescent inhibitors and
membrane-impermeant sulfonamides have recently
been used as proof-of-concept tools, demonstrating
that CA IX is an interesting target for anticancer drug
development.
Introduction
The a-carbonic anhydrases (CAs, EC 4.2.1.1) are
widespread metalloenzymes in higher vertebrates includ-
ing humans [1]. So far, 16 isozymes have been identified
that differ in their subcellular localization, catalytic activ-
ity and susceptibility to different classes of inhibitors.
Some of these isozymes are cytosolic (CA I, CA II, CA
III, CA VII and CA XIII), others are membrane bound
(CA IV, CA IX, CA XII and CA XIV), two are mitochondrial
(CA VA and CA VB), and one is secreted in saliva (CA VI).
The recently reported CA XV isoform is not expressed in
humans or in other primates (where it is encoded by a
pseudogene), but it is abundant in rodents and other
higher vertebrates [2]. Three acatalytic forms are also
known, called CA-related proteins (CARPs): CARP VIII,
CARP X and CARP XI [1]. In humans, CAs are present in
various tissues such as the gastrointestinal tract, the
reproductive tract, the nervous system, kidneys, lungs,
skin and eyes, among others [1].
These Zn2+ enzymes have crucial physiological
roles [1]. Most CAs are efficient catalysts for theCorresponding author: Supuran, C.T. (claudiu.supuran@unifi.it).
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www.sciencedirect.com 0165-6147/$ – see front matter  2006 Elsevier Ltd. All rights reservereversible hydration of carbon dioxide to bicarbonate
(CO2 + H2O$ HCO3 + H+), the only physiological
reaction in which they are involved [1]. Membrane-bound
CAs, such as CA IX, have an extracellular active site and
can provide the H+ or HCO3
 ions formed during catalytic
turnover for various physiological processes, among which
is extracellular acidification [1]. Many CA isoforms are
thus involved in essential cellular processes such as
respiration and acid–base regulation, electrolyte secretion,
bone resorption, calcification and biosynthetic reactions
that require HCO3
 as a substrate (e.g. lipogenesis,
gluconeogenesis and ureagenesis) [1].
Recently, it has been shown that two CA isozymes (CA
IX and CA XII) are prominently associated with and
overexpressed in many tumors, where they are involved
in crucial processes connected with cancer progression
and response to therapy [3–5]. The first CA found to be
associated with cancers was CA IX, as reported in 1992 by
Pastorekova´ et al. [3,5]. The second one, CA XII, was
subsequently shown to be coexpressed with CA IX in
several tumor tissues and was also found in a wider range
of normal tissues [3]. Because many CA isoforms (includ-
ingCA IX) are associatedwith anion exchangers or sodium
bicarbonate cotransporters, with which they form
metabolons (protein complexes in which the two proteins
are in close functional and physical contact) [6], it has been
both suggested and demonstrated that they are important
in the transport of ions across biologicalmembranes and in
the secretion of electrolytes in many tissues or organs
[1,6].
In this review we focus on CA IX, an interesting protein
that was initially reported as a ‘tumor antigen’ and has
been subsequently shown to belong to the CA gene family.
CA IX possesses a more complicated organization of the
protein chain compared with the classical CA isoforms,
such as CA I or CA II, identified originally [1,3]. Subse-
quent work has shown that CA IX is expressed in only a few
normal tissues, but is ectopically induced and highly over-
expressed in many types of tumor, mainly owing to its
strong transcriptional activation by hypoxia via the tran-
scription factor hypoxia-inducible factor (HIF-1) [7–9]. CA
IX has since been shown to serve as a surrogate marker of
hypoxia and as a prognostic indicator for many cancers,
which unfortunately are often hypoxic [3,9,10]. CA IX has
also been shown to be involved in both the pH regulation
and cell-adhesion processes caused by tumor metabolism
[3,9].d. doi:10.1016/j.tips.2006.09.002
Box 1. CA IX and its regulation in hypoxia
The transcription factor HIF-1 is a heterodimer consisting of an
inducible subunit (HIF-1a) and a constitutively expressed subunit (HIF-
1b) [7]. In keeping with its name, HIF-1 becomes active under
conditions of hypoxia by means of stabilization and/or expression
of the HIF-1a subunit, which is unstable and almost undetectable
under normal conditions. Proteins with an oxygen-dependent prolyl-
4-hydroxylase domain (PHD) covalently modify a region in HIF-1a,
known as the ‘oxygen-dependent degradation domain’, by hydro-
xylating proline residues. Hydroxylated HIF-1a subsequently forms
hydrogen bonds with side chains on the von Hippel–Lindau tumor
suppressor protein (pVHL), which in turn promotes polyubiquitination
of HIF-1a, followed by degradation by the 26S proteasome [7].
Under hypoxic conditions, binding of pVHL to HIF-1a is inhibited,
resulting in accumulation of HIF-1a and its dimerization with the
constitutive HIF-1b subunit. Thus, hypoxia attenuates proline
hydroxylation owing to the inactivity of PHDs in the absence of
oxygen, resulting in stabilization of HIF-1a and its non-recognition
by pVHL. Association of HIF-1a with the HIF-1b subunit leads to the
formation of HIF-1, resulting in the expression of targets that
contain hypoxia-responsive element (HRE) sites [7]. Target genes
include, among others, glucose transporters (GLUT-1 and GLUT-3),
which contribute to glucose metabolism; vascular endothelial
growth factor, which triggers neoangiogenesis; and last but not
least, CA IX, which is involved in pH regulation and cell adhesion
[3,9] (Figure I). In some cancer cells, the gene encoding pVHL is
mutated, leading to the strong upregulation of CA IX (up to 150-
fold) as a consequence of constitutive HIF activation [8]. In a
renal carcinoma cell line, CA IX is also regulated by promoter
methylation – an epigenetic mechanism involved in the control of
many cancer-related genes [26].
Figure I. Regulation of hypoxia-induced gene expression mediated by the HIF-1 transcription factor. Adapted, with permission, from Refs [3,48].
Opinion TRENDS in Pharmacological Sciences Vol.27 No.11 567Numerous potent (and sometimes selective) inhibitors
of CA IX have been developed in the past few years on the
basis of the idea that inhibition of tumor acidification
processes and re-establishment of amore normal pHmight
lead to regression of the tumor, especially when used in
combination with classical anticancer drugs. Indeed, pre-
liminary results have shown that this is the case, establish-
ing CA IX as a novel drug target for the development of
both diagnostic tools and therapeutic agents.
Each of these aspects will be discussed here, with
emphasis on how inhibitors of an enzyme that has been
known for decades (the classical CA isoforms were discov-
ered in the 1930s and characterized in the 1960s [1]) could
lead to completely new applications owing to the revolu-
tionary discovery of Pastorekova´ et al. [5] that a protein
with this type of simple and unexpected enzymatic activity
is so abundant in tumors.
Cancer-related CA IX
In tumors, hypoxia stems from an inadequate supply of
oxygen, which is primarily a pathophysiological conse-
quence of structurally and functionally disturbed micro-
circulation and the deterioration of O2 diffusion processeswww.sciencedirect.com[7]. Solid tumor growth is limited by vascularization, which
is necessary for oxygen and nutrient supply.
Tumor hypoxia usually occurs at a distance of
100–200 mm from blood vessels [7,8] and seems to be
strongly associated with tumor propagation, malignant
progression and resistance to chemo- and radiotherapy
[6,8]. Hypoxia can regulate the expression of several genes,
including that encoding CA IX, through binding of the
transcription factor HIF-1 to a hypoxia-responsive element
in the gene. CA IX is thus a target of HIF-1 and functions as
an intrinsic marker of hypoxia in a wide spectrum of
tumors [9,10].
CA IX expression and distribution
The expression of CA IX is upregulated by hypoxia
(through the HIF-1 activation cascade) and is downregu-
lated by the wild-type von Hippel–Lindau tumor suppres-
sor protein [8,9] (Box 1).
The distribution of CA IX in human tissues is unusual:
this isoform is significantly expressed in only a few normal
tissues, and this expression is either decreased or lost
during carcinogenesis [3]; however, CA IX is ectopically
expressed in numerous tumors, predominantly
Figure 2. Domain organization of the CA IX protein [3,5].
Figure 1. Distribution of CA IX in human normal and tumor tissues. Adapted, with
permission, from Ref. [3].
568 Opinion TRENDS in Pharmacological Sciences Vol.27 No.11carcinomas, that are mostly derived from tissues that do
not normally express CA IX (Figure 1). This atypical
differential expression pattern enables us to designate
CA IX as a tumor-associated protein and to use it as a
biomarker of cancer [3,11–20].
Of the normal tissues that do contain high levels of CA
IX, mucosa of the glandular stomach shows the most
abundant expression [3]. Therein, CA IX is localized to
the basolateral surfaces of all types of epithelial cell. Its
roles in this organ might involve maintaining both gastric
mucosa integrity and the balance between cell differentia-
tion and proliferation [3]. Expression of CA IX frequently
declines or disappears in gastric cancers, possibly as a
consequence of neoplastic changes that involve dediffer-
entiation [3]. Such studies suggest that CA IX has a crucial
role as a differentiation factor involved in morphogenesis
and homeostasis of the gastric epithelium [3]. Gallbladder
epithelial cells but not hepatocytes also show high levels
and basolateral localization of CA IX [3]. In biliary epithe-
lial tumors, expression of CA IX also decreases with an
increasing grade of malignancy, indicating a similar rela-
tionship of CA IX to cell differentiation as described for the
gastric mucosa [3].
Furthermore, CA IX has been found in the basolateral
membranes of acinar and ductal pancreatic cells: its
expression is increased in hyperplastic areas and persists
in some malignant pancreatic tumors [3]. CA IX is present
in the intestinal epithelium, where it is confined to the
deep cryptal areas characterized by high cell proliferation
[3]. Expression of CA IX is increased in superficialwww.sciencedirect.comcolorectal adenomas and in both superficial and deep parts
of malignant carcinomas [3]. CA IX expression is also
retained in both mesotheliomas and some germ cell
tumors. The only organ that does not show any CA IX
positivity, irrespective of whether it is healthy or cancer-
ous, is the prostate gland [3].
Human tumors showing a high ectopic expression of CA
IX in a significant proportion of specimens include
carcinomas of the uterine cervix, kidney, esophagus, lung,
breast, brain and vulva, among others [3,11–20] (Figure 1).
Comparison of the cDNA sequence of CA IX expressed in
HeLa cervical carcinoma cell lines with that expressed in
normal stomach found no differences between the two
proteins [3], indicating that mutations are not responsible
for the association of CA IX with tumors and suggesting
that cancer-related regulatory pathways are involved in
controlling CA IX expression [3]. Furthermore, as part of
the hypoxic acidification machinery, CA IX has been sug-
gested to facilitate nucleolar sequestration of the von
Hippel–Lindau tumor suppressor protein and activation
of HIF-1, which together represent a recently described
pH-dependent mechanism with a proposed protective role
in reoxygenated cells [21].
Structure and catalytic activity of CA IX
Unlike other CA isoforms that possess one polypeptide
chain comprising only the catalytic domain [1], CA IX is
a multidomain, transmembrane protein with a more com-
plex organization (Figure 2). This isoform comprises (i) a
small intracytosolic tail with an unknown function; (ii) a
short transmembrane segment; (iii) the extracellular cat-
alytic domain, which shows high sequence homology to the
catalytic domain of other a-CAs [3,5]; (iv) a proteoglycan-
like domain unique to CA IX, which is crucial to the cell-
adhesion processes in which this protein is involved [3];
and (v) a short signal peptide. Many experiments (see
later) have been performed with protein constructs lacking
either the proteoglycan-like domain or the catalytic
domain in order to understand the relevance of the various
domains to its function and role in tumorigenesis [3,5,22–
24]. The X-ray crystal structure of CA IX is unknown, but
polyacrylamide gel electrophoresis experiments have led to
the conclusion that CA IX forms trimers linked by disulfide
bonds [22–24].
Many CAs expressed in humans have high catalytic
activity for their physiological reaction (i.e. hydration of
CO2 to HCO3
 and H+), and CA IX is among these high-
activity isoforms [1,3]. Amino acid sequencing of CA IX
has shown that it contains four cysteine residues, three of
them in the catalytic domain and the fourth in the region
proximal to the transmembrane anchor (Figure 2).
Cys156 and Cys336 are in positions analogous to
Opinion TRENDS in Pharmacological Sciences Vol.27 No.11 569intramolecular disulfide-bond-forming cysteines in other
CA isoforms [1,3], whereas the other two, Cys174 and
Cys409, probably participate in the formation of
intermolecular disulfide bonds in the above-mentioned
trimers. A single N-glycosylation site has been predicted
in the catalytic domain at position 346. The cytoplasmic
tail of CA IX contains three putative phosphorylation
sites (Thr443, Ser448 and Tyr449), the possible regula-
tory roles of which remain to be investigated [3,9]. As in
all other a-CA isozymes investigated so far [1], the cat-
alytic domain in CA IX contains an essential Zn2+ ion
coordinated by three histidine residues (His94, His96 and
His119 in CA I numbering [1]) and a water molecule,
which, by deprotonation assisted by the active-site resi-
due His64 (CA I numbering for historical reasons [1]),
leads to the zinc hydroxide form that functions as the
nucleophilic species in the catalytic cycle [25].
As mentioned above, CA IX is a highly active human
a-CA, and its catalytic properties for the CO2 hydration
reaction are comparable to those of CA II, a perfectly
evolved catalyst [1], with the kinetic parameters
kcat = 3.8  105 s1 and kcat/Km = 5.5  107 M1 s1 (where
kcat is the catalytic rate constant and Km is the Michaelis
constant) [1,25]. CA IX is susceptible to inhibition by
anions and sulfonamides or sulfamates, as are all of the
other a-CA isoforms [1,25]: the inhibitors coordinate the
Zn2+ ion directly in the active-site cavity (see later) and
participate in various other favorable interactions with
amino acids situated in both the hydrophobic and the
hydrophilic halves of the active site [1,9]. Many low-
nanomolar inhibitors of CA IX have been detected in the
past several years [1,9,25].
Roles of CA IX in cancer biology
In tumors other than renal cell carcinomas, CA IX has a
predominantly perinecrotic distribution that is typical of
hypoxia-regulated proteins [3,11,14–20]. Necrosis usually
develops in regions that are most distant from the func-
tional blood vessel and suffer from long-lasting severe
hypoxia (or even anoxia), which does not permit the
affected cells to survive [3]. By contrast, cells that are
localized nearer the functional blood vessel (in the perine-
crotic regions) and are not exposed to such high stress can
adapt to low-oxygen conditions via the induction of many
HIF-1 targets including CA IX.
Studies investigating the relationship of CA IX to
hypoxia in a large series of specimens of different tumor
types have confirmed the perinecrotic pattern of CA IX
expression [3]. For example, expression of CA IX highly
correlates with the level of hypoxia measured in cervical
tumors by needle electrodes or by incorporation of the
chemical hypoxia marker pimonidazole [3], with necrosis
and high tumor grade in breast and lung carcinomas [3],
and with necrosis, microvascular density and advanced
stage in head and neck cancer [3]. On the basis of these
data, CA IX has been proposed as a reliable intrinsic
marker of tumor hypoxia [3,26]. Such a marker would be
extremely helpful in clinical practice because its detection
by themonoclonal antibodyM75 developed by Pastorekova´
and Pastorek [3] does not require an invasive approach
(e.g. needle electrodes) or metabolic incorporation (e.g.www.sciencedirect.compimonidazole) before biopsy and can be standardized for
routine use [3].
As mentioned earlier, hypoxia, via the HIF-1 cascade,
leads to strong overexpression of CA IX in many tumors
with the overall consequence that the imbalance in pH in
the tissue is increased. Indeed, most hypoxic tumors are
acidic (pH  6), in contrast to normal tissues (pH  7.4).
The role of CA IX in the acidification processes of hypoxic
tumors has been demonstrated only recently by one of our
groups and by Pastorekova´’s group [27]. Using Madin–
Darby canine kidney epithelial cells constitutively expres-
sing human CA IX, Svastova et al. [27] showed that CA IX
can decrease the extracellular pH (pHe) of the cultivated
cells. CA-IX-selective sulfonamide inhibitors (type 1 and 2;
see later) reduced acidification of the medium, by inhibit-
ing the catalytic activity of the enzyme and thus the
generation of H+ ions, and bound only to hypoxic cells
expressing CA IX (and not to the same cells expressing
a similar level of CA IX under normal conditions) [27]. In
addition, deletion of the active site in the catalytic domain
of CA IX was shown to reduce acidification of the medium,
but the sulfonamide inhibitors did not bind to the active
site of these mutant proteins [27].
It is thus clear that tumor cells decrease their pHe both
by the production of lactic acid (owing to the high glycolysis
rate), and by CO2 hydration catalyzed by the tumor-
associated CA IX isoform, which possesses an extracellular
catalytic domain [28] (Figure 3). Low pHe has been asso-
ciated with tumorigenic transformation, chromosomal
rearrangements, extracellular matrix breakdown, migra-
tion and invasion, induction of cell growth factors, and
protease activation [3,29].
In a recent study using RNA interference, Robertson
et al. [30] found interesting evidence supporting the action
of CA IX in tumor cell invasion. In normal tissues such as
gastrointestinal epithelial cells, CA IX regulates morpho-
genesis and homeostasis by controlling cell proliferation
and differentiation [25]. CA-IX-deficient mice constructed
by targeted disruption of the Ca9 gene (encoding CA IX),
show gastric hyperplasia with aberrant cell lineage devel-
opment. The unique proteoglycan-like domain present in
CA IX has been thus implicated in cell adhesion and
differentiation [22,23]. CA IX is probably also involved
in providing bicarbonate used as a substrate for cell
growth, because it has been established that bicarbonate
is required in the synthesis of pyrimidine nucleotides [31].
Chemoresistance
The presence of an H+ gradient across the membrane of
tumor cells also has interesting implications for che-
motherapy [32]. Acidification of the solid tumor milieu
might decrease the uptake of weakly basic anticancer
drugs, leading to chemoresistance [33]. Most anticancer
drugs are transported by either active transport or passive
diffusion into cells, where they frequently undergo further
metabolism [29]. Because all of these processes are pH
sensitive, the cytotoxic activity of anticancer drugs could
depend on both intracellular pH (pHi) and pHe.
In particular, drugs that are weakly ionized enter cells
by passive diffusion in their non-ionized form. Such drugs
will tend to partition preferentially across the cell
Figure 3. Molecular mechanisms involved in pH regulation and ion transport in cancer cells. Lactic acid is produced from glucose by glycolysis. The lactate and H+ ions are
exported from the extracellular fluid by the monocarboxylate carrier (i). The Na+–H+ antiporter (ii), which is activated in transformed cells, exports H+ and imports Na+,
contributing to high levels of intracellular Na+, a common feature in tumor cells. Several other protein machines are used by cancer cells to maintain intracellular neutrality,
including ATP-dependent Na+–K+ antiporters (iii), H+ channels (iv), and the plasma membrane proton pump H+–ATPase (v). H2O and CO2 provided by the cytosolic isozyme
CA II are exported through aquaporins and used by cell-surface CAs to produce HCO3
 (vi). Conversely, CA IX and CA XII produce HCO3
 ions outside the cell, which are
transported inside by HCO3
–Cl anion exchangers (vii) and used by the cytosolic isozyme CA II. Adapted, with permission, from Refs [3,12,29].
570 Opinion TRENDS in Pharmacological Sciences Vol.27 No.11membrane into the compartment where their ionized
form predominates [29]. For example, primary amines
tend to be excluded from, and carboxylic acids tend to be
accumulated by, the more alkaline intracellular compart-
ment. In addition, the toxicity of several drugs is sensitive
to variations in pH as a result of various mechanisms that
are not dependent on ionization-dependent diffusion
through the cell membrane [29]. For example, the toxicity
of melphalan is enhanced by pHe modification without an
increase in uptake or accumulation.
Various strategies for altering pHi and pHe have been
tried in the quest for new anticancer therapies for solid
tumors. Enhancing the pHe has been found to improve the
cytotoxic efficacy of the weakly basic drugs mitoxantrone,
paclitaxel and topotecan [32]. Furthermore, the delay in
tumor growth induced by the weak base doxorubicin is
enhanced by increasing the pHe of tumors after chronic
ingestion of a sodium bicarbonate solution [33]. CA inhi-
bitors have been previously shown to elicit synergistic
effects when used in combination with other chemother-
apeutics agents in animal models [34]. Targeting CA IX
with specific inhibitors or antibodies should contribute, on
the one hand, to enhancing the action of weakly basic drugs
and, on the other hand, to reducing the acquisition of
metastatic phenotypes by controlling the pH imbalance
in the tumor cells.
Targeting CA IX in cancer therapy
The involvement of some CAs and of their sulfonamide
inhibitors in cancer has been investigated recentlywww.sciencedirect.com[1,3,9,27]. Many potent CA inhibitors derived from acet-
azolamide, ethoxzolamide and benzenesulfonamides have
been shown to inhibit the growth of several tumor cell lines
in vitro and in vivo [35,36]. Many of the cell lines used are
known to express either of the tumor-associated CA IX and
CA XII isoforms, or both; thus, it is not impossible that the
observed antiproliferative effects of sulfonamides are
mediated by inhibition of these cancer-related isozymes
[3,35,36].
However, CA IX and CA XII seem to be functionally
linked to tumor metabolism and microenvironment in
vivo rather than in vitro [9]. Xiang et al. [37] have
demonstrated that acetazolamide can suppress tumor
metastasis in vivo, at least in part, by both inhibiting
the expression of aquaporin, a water channel protein that
might be implicated in vascular permeability and inter-
stitial fluid pressure in tumors, and strongly inhibiting
several CA isozymes, among which are the tumor-
associated isoforms CA IX and XII, and the ubiquitous
cytosolic isoform CA II [1,9,27,35,36]. Aquaporin is also
thought to be involved in CO2 transport processes, and
suppression of its expression by sulfonamide or sulfamate
CA inhibitor drugs might constitute an additional
mechanism (poorly understood at this moment) explain-
ing the antitumor effects of such compounds [36–38].
Nevertheless, the antiproliferative effect of CA inhibitors
might also be due to their effect on other CA isoforms such
as CA II or CA V, which provide the bicarbonate substrate
for cell growth in carboxylation reactions involved in
lipogenesis, nucleotide biosynthesis and gluconeogenesis,
Opinion TRENDS in Pharmacological Sciences Vol.27 No.11 571among others, thereby limiting the unrestrained
proliferation of the tumor cells [1,9,31].
Indisulam and other CA IX inhibitors
Indisulam is a sulfonamide derivative (originally called
E7070) discovered by Owa’s group [39] through screening
studies that demonstrated its powerful anticancer activity.
Indisulam has been recently shown to act as a nanomolar
inhibitor of CA IX [38]. Its mechanism of action is not clear,
however, because the drug is involved in perturbation of
the cell cycle in the G1 and/or G2 phases, in downregula-
tion of cyclins, in reduction of CDK2 activity, in inhibition
of phosphorylation of the retinoblastoma protein and
in differential expression ofmolecules known to participate
in cell adhesion, signaling and immune response, in
addition to its inhibitory properties against CA IX
[39,40]. Indisulam shows in vivo efficacy against human
tumor xenografts in nude mice, where it exhibits
significant antitumor effects [41], and has progressed to
Phase I and Phase II clinical trials for treatment of solid
tumors.
Some of the most interesting CA IX inhibitors currently
available, among the many derivatives reported [42–44],
are the compounds investigated by Svastova and et al. [27]
for their in vivo role in tumor acidification (Figure 4,
structures 1 and 2). These compounds are especially inter-
esting because derivative 1 is a fluorescent sulfonamide
with high affinity for CA IX (inhibition constant,
Ki = 24 nM) [43] that has been shown to be useful as a
fluorescent probe for hypoxic tumors [27]. This inhibitor
binds to CA IX only under conditions of hypoxia in vivo [27].
Although the biochemical rational for this phenomenon is
not understood at present, these properties might be
exploited for designing diagnostic tools for the imaging
of hypoxic tumors [27,44,45].Figure 4. Sulfonamide inhibitors demonstrate the involvement of CA IX in tumor
acidification processes. The sulfonamide inhibitors used include the fluorescent
compound 1 and the membrane-impermeant pyridinium 2 [27,32–45]. Shown is
the X-ray crystal structure of the complex between CA II and 2, revealing the
inhibitor (green), the Zn-2+-coordinating residues His94, His96, and His119, and the
Zn2+ ion (in ball-and-stick representation). The protein backbone is shown in
ribbon representation [44].
www.sciencedirect.comBy contrast, compound 2, which is also a strong CA IX
inhibitor (Ki = 14 nM) [44], belongs to a class of positively
charged, membrane-impermeant compounds previously
reported by Scozzafava, A. et al. [46]. These compounds
are highly attractive for targeting CA IX with its
extracellular active site, because they do not inhibit intra-
cellular CAs and thus might lead to drugs with fewer
side-effects compared with those that are currently avail-
able (acetazolamide is the prototypical one), which indis-
criminately inhibit all CA isoforms [25]. The X-ray crystal
structure of compound 2 in adduct with CA II (which has an
active site similar to that of CA IX, as shown recently by
homology modeling [43,47]) has been solved [44]. The
positively charged pyridinium derivative 2 favorably binds
in the enzyme active site, where the deprotonated sulfo-
namide moiety coordinates with the catalytically essential
Zn2+ ion (Figure 4). It also participates in many other
favorable interactions with amino acids in the active site
cavity, among which is a stacking between the trimethyl-
pyridinium ring of the inhibitor 2 and the phenyl ring of
Phe131, a residue that is important in the binding of
inhibitors to CAs [44]. A similar mode of binding has
subsequently been reported for the fluorescein derivative
1 [43].
Thus, such structures can be used for the rational drug
design of more isozyme-IX-selective and potent CA inhibi-
tors [42,43]. We should mention that, because the X-ray
structure of CA IX is not yet available, most studies have
used the CA II structure for modeling and designing CA IX
inhibitors. We therefore stress again that positively
charged compounds of which 2 is a representative might
have the advantage of selectively inhibiting only CA IX in
vivo, owing to their membrane impermeability [44].
Concluding remarks and future perspectives
With its overexpression in many cancer tissues but not in
their normal counterparts, CA IX constitutes an interest-
ing target for novel approaches to anticancer therapy. CA
IX has been shown to acidify the extratumoral medium,
contributing to both the acquisition of metastasic pheno-
types and chemoresistance to weakly basic anticancer
drugs. Consequently, further research needs to be done
in the field of the tumor-associated CA IX isozyme to
understand better its exact role in cancer.
CA-IX-selective inhibitors constitute interesting tools
with which to study the physiological or pathological
effects of CA IX. Indisulam, a sulfonamide anticancer drug,
is already in Phase II clinical trials. In addition to its
hypothetical action in perturbing the cell cycle, indisulam
acts as a potent inhibitor against CA IX but it is difficult to
quantify at present the contribution of inhibition of CA IX
to the overall antitumor effects of the drug. Given that
several pathways contribute to tumor growth, however,
anti-tumor activity might be increased by agents that
target multiple molecules, including CA IX, or by the
combination of several agents to facilitate inhibition of
several mechanisms.
Recently, the design of CA-IX-selective inhibitors
containing boron has been proposed [42]. Sulfonamides,
sulfamates and sulfamides have been synthesized by
derivatization reactions of 4-carboxy-, amino- or
572 Opinion TRENDS in Pharmacological Sciences Vol.27 No.11hydroxy-phenylboronic acid pinacol esters with amino- or
isothiocyanato-substituted aromatic or heteroaromatic
sulfonamides or by sulfamoylation reactions of amines or
phenols with sulfamoyl chloride [42]. Many of these
derivatives strongly inhibit CA IX, with Ki values in the
range 7.3–89 nM [42]. Because hypoxic tumors highly over-
express CA IX, the design of boron-containing inhibitors
with high affinity for this tumor-associated isozyme might
lead to important advances in boron neutron capture
therapy that target such tumors, which are non-responsive
to both classical chemo- and radiotherapy. Indeed, accu-
mulation of the boron-containing inhibitor in the tumor
might lead to the selective destruction of only the diseased
part with no appreciable harm to healthy tissues.
In conclusion, many biochemical, physiological and
pharmacological data point to the potential use of inhibi-
tion of tumor-associated CA isozyme IX in the manage-
ment of hypoxic tumors that do not respond to classical
chemo- and radiotherapy. These compounds provide the
possibility of developing both diagnostic tools for the non-
invasive imaging of these tumors and therapeutic agents
that might perturb the extratumoral acidification process
in which CA IX is involved. Many classes of highly effective
in vitro CA IX inhibitors have been developed and the
pharmacological evaluation of some of them has recently
begun.Much pharmacological work is, however, warranted
to understand whether a successful new class of antitumor
drugs might be developed from these preliminary but
encouraging observations.
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